ROSEN Law Firm Advises AstraZeneca PLC Investors on Class Action Lawsuit

New York, New York--(Newsfile Corp. - December 30, 2024) - Background: The Rosen Law Firm, recognized globally as a leader in investor rights, has initiated a class action lawsuit on behalf of individuals who purchased securities of AstraZeneca PLC (NASDAQ: LON:) between February 23, 2022, and December 17, 2024 (the "Class Period"). This lawsuit has been filed to address potential wrongdoings that may have affected investors during this period.

Important Information: If you bought AstraZeneca securities during the specified Class Period, you might have the right to claim compensation. Notably, these potential claims come with no up-front cost due to the contingency fee arrangement offered by the firm.

Action Steps: Investors looking to join the class action can find more information by visiting this link. Alternatively, you can reach out to Phillip Kim, Esq. at 866-767-3653 or via email at [email protected] for personalized information regarding the class action. It is crucial for potential lead plaintiffs to file their motion with the Court by February 21, 2025. A lead plaintiff serves as a representative for the class in guiding the litigation process.

Why Choose Rosen Law Firm: It is advisable for investors to select experienced legal counsel. The Rosen Law Firm has a proven track record in successfully leading securities class actions and has recovered vast sums for investors, including over $438 million in 2019. The firm has consistently ranked highly for its settlements, achieving recognition as the top firm by ISS Securities Class Action Services in 2017. Founding partner Laurence Rosen has been acknowledged by Law360 as a leader in the plaintiffs' bar.

Details of the Case: The lawsuit alleges that during the Class Period, AstraZeneca's management made materially false or misleading statements, failing to disclose critical issues such as: (1) involvement in insurance fraud in China; (2) the legal consequences leading to the detention of AstraZeneca's China President by authorities; (3) understated legal risks faced by the company; and (4) potential damage to AstraZeneca's business operations in China once these truths were revealed. The claims suggest significant losses to investors, correlating with the exposure of these truths.

If you wish to participate in the AstraZeneca class action, please refer to this link or contact Phillip Kim, Esq. for assistance.

Next Steps: Note that no class has yet been certified, which means that until then, investors are not represented by counsel unless they choose to retain one. Individuals have the option to remain passive class members or to select their own counsel.

Stay updated by following the Rosen Law Firm on their LinkedIn LinkedIn page or on Twitter Twitter account.

Attorney Advertising: Previous results do not guarantee similar outcomes.

AstraZeneca, lawsuit, investors